Investigating efficacy of “microbiota modulation of the gut-lung Axis” combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial

Investigating efficacy of “microbiota modulation of the gut-lung Axis” combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial

Abstract Background Most NSCLCs metastasised out of the lungs at the time of diagnosis and cannot be surgically removed . Cytotoxic chemotherapy drugs have become the main treatment in recent decades, especially in patients with NSCLC without EGFR, ALK, and ROS gene mutations. The prognosis of lung...

Full description

Bibliographic Details
Main Authors: Qing Xia, Guojie Chen, Yanbei Ren, Tiansheng Zheng, Changxing Shen, Ming Li, Xiangyun Chen, Hong Zhai, Zhuang Li, Jianfang Xu, Aiqin Gu, Meiling Jin, Lihong Fan
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Gut-lung axis microecology
Chemotherapy
Probiotics
Online Access:https://doi.org/10.1186/s12885-021-08448-6

Internet

https://doi.org/10.1186/s12885-021-08448-6

Similar Items